Catalent Receives NYSE Notice Regarding Late Form 10-K Filing
15 Setembro 2023 - 8:00AM
Business Wire
Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the
leader in enabling the development and supply of better treatments
for patients worldwide, today announced that, on September 14,
2023, it received a notice (the “NYSE Notice”) from the New York
Stock Exchange (the “NYSE”) that the Company is not in compliance
with the NYSE’s continued listing requirements under the timely
filing criteria established in Section 802.01E of the NYSE Listed
Company Manual, because the Company did not timely file its Annual
Report on Form 10-K for the fiscal year ended June 30, 2023 (the
“Form 10-K”) with the Securities and Exchange Commission (the
“SEC”).
The NYSE Notice has no immediate effect on the listing of the
Company’s common stock on the NYSE. The NYSE Notice informed the
Company that, under NYSE rules, the Company has six months from
September 13, 2023 to regain compliance with the NYSE listing
standards by filing the Form 10-K with the SEC. The NYSE further
noted that, if the Company fails to file the Form 10-K within the
six-month period, the NYSE may grant, at its sole discretion, an
extension of up to six additional months for the Company to regain
compliance, depending on the specific circumstances. The NYSE
Notice also notes that the NYSE may nevertheless commence delisting
proceedings at any time if it deems that the circumstances
warrant.
As previously reported in the Company’s Notification of Late
Filing on Form 12b-25 filed with the SEC on August 30, 2023 (the
“Form 12b-25”), the Company was unable to file the Form 10-K within
the prescribed period because it requires additional time to
complete its procedures related to management’s assessment of the
effectiveness of its internal controls over financial reporting as
of June 30, 2023 and other closing procedures. Subsequent to filing
the Form 12b-25, the Company continued to dedicate significant
resources to the completion of such procedures, but was unable to
file the Form 10-K by September 13, 2023, the end of the extension
period provided by the Form 12b-25. The Company requires additional
time to complete such procedures for the fourth quarter of fiscal
year 2023.
Based on currently available information and subject to the
completion of the preparation of the Company’s financial statements
and assessment of the Company’s internal controls over financial
reporting and completion of the audits thereof, the Company does
not expect any material change to the financial results to be
included in the Form 10-K compared to the financial information
reported in the earnings release the Company furnished to the SEC
on the Company’s Current Report on Form 8-K filed on August 29,
2023.
The Company is working diligently to complete the necessary work
to file the Form 10-K as soon as practicable and currently expects
to file the Form 10-K within the six-month period granted by the
NYSE Notice; however, there can be no assurance that the Form 10-K
will be filed within such period.
About Catalent
Catalent, Inc. (NYSE: CTLT), is the global leader in enabling
pharma, biotech, and consumer health partners to optimize product
development, launch, and full life-cycle supply for patients around
the world. With broad and deep scale and expertise in development
sciences, delivery technologies, and multi-modality manufacturing,
Catalent is a preferred industry partner for personalized
medicines, consumer health brand extensions, and blockbuster drugs.
Catalent helps accelerate over 1,500 partner programs and launch
over 150 new products every year. Its flexible manufacturing
platforms at over 50 global sites supply approximately 70 billion
doses of nearly 8,000 products annually. Catalent’s expert
workforce of nearly 18,000 includes more than 3,000 scientists and
technicians. Headquartered in Somerset, New Jersey, the company
generated nearly $4.3 billion in revenue in its 2023 fiscal year.
For more information, visit www.catalent.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding management’s ongoing review of its fourth fiscal quarter
and fiscal 2023 financial statements and the Company’s ability to
regain compliance with the NYSE’s listing standards. These
forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause actual future events, results or
achievements to be materially different from the Company’s
expectations and projections expressed or implied by the
forward-looking statements. Important factors include, but are not
limited to those discussed under the caption “Risk Factors” in the
Company’s Annual Report on Form 10-K for the year ended June 30,
2022 (as amended), the Company’s Quarterly Report on Form 10-Q for
the three and nine months ended March 31, 2023, and the Company’s
other filings with the SEC. Forward-looking statements speak only
as of the date of this press release and are based on information
available to the Company as of the date of this press release, and
the Company assumes no obligation to update such forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230915959542/en/
Investor Contact: Paul Surdez (732) 537-6325
investors@catalent.com Media Contact: Bernie Clark +1 (732)
537-6400 media@catalent.com
Catalent (NYSE:CTLT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Catalent (NYSE:CTLT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024